Evidence map›Paper›PMID 35976571›Full record

ArticleClinical pharmacokinetics2022

Correction to: Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases.

Ying Fei Li, Francois Pierre Combes, Matthias Hoch, Sebastien Lorenzo, Sherwin K B Sy, Yu-Yun Ho

Open access · bronzeAbstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Clinical pharmacokinetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Ying Fei LiNovartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. ying_fei.li@novartis.com.ORCID http://orcid.org/0000-0002-1406-8538
Francois Pierre CombesNovartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.ORCID http://orcid.org/0000-0002-8637-7372
Matthias HochNovartis Institute for Biomedical Research, Basel, Switzerland.
Sebastien LorenzoNovartis Pharmaceuticals Corporation, Basel, Switzerland.
Sherwin K B SyNovartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.ORCID http://orcid.org/0000-0001-6405-9130
Yu-Yun HoNovartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Novartis (Switzerland) · CHNovartis (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID35976571
OpenAlexW4292259080

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.